VEXAS综合征患者的静脉与动脉血栓形成
该研究评估了119例VEXAS综合征患者的静脉和动脉血栓形成情况及其与临床结局和生存的相关性。血栓形成发生于49%的患者,主要为静脉血栓栓塞(VTE;41%),其中近三分之二为无诱因、41%复发、20%发生在抗凝治疗期间。从症状发作起VTE的1年累积发生率为17%,5年累积发生率为40%;动脉血栓1年累积发生率为6%,5年累积发生率为11%。中位随访4.8年时整个队列总生存率为88%,有无血栓形成患者间生存无差异(P = .8)。
要点
- VEXAS综合征患者血栓形成发生率为49%,以VTE为主(41%)。
- VTE的1年累积发生率为17%,5年累积发生率为40%。
- M41L与肺栓塞独立相关(多因素OR 16.94)。
核心结论
- VEXAS综合征患者VTE风险高;除非有强烈禁忌,在高风险情况下应进行血栓预防。
研究设计与样本
- 对119例VEXAS综合征患者进行静脉和动脉血栓形成评估,并将血栓形成与临床结局和生存进行相关性分析。
主要发现
- 血栓形成发生于49%的患者,其中VTE占41%;VTE中近三分之二为无诱因,41%复发,20%发生在抗凝治疗期间。
- 从症状发作起VTE的1年累积发生率为17%,5年累积发生率为40%。
- 心脏和肺部炎症表现与VTE发生时间相关。
- 动脉血栓1年累积发生率为6%,5年累积发生率为11%。
关键数值与推荐
- VTE累积发生率:从症状发作起1年为17%,5年为40%。
- 动脉血栓累积发生率:1年为6%,5年为11%。
临床怎么用
- 除非有强烈禁忌,在高风险情况下应进行血栓预防。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, caused by somatic mutations in UBA1, is an autoinflammatory disorder with diverse systemic manifestations. Thrombosis is a prominent clinical feature of VEXAS syndrome. The risk factors and frequency of thrombosis in VEXAS syndrome are not well described, due to the disease's recent discovery and the paucity of large databases. We evaluated 119 patients with VEXAS syndrome for venous and arterial thrombosis and correlated their presence with clinical outcomes and survival. Thrombosis occurred in 49% of patients, mostly venous thromboembolism (VTE; 41%). Almost two-thirds of VTEs were unprovoked, 41% were recurrent, and 20% occurred despite anticoagulation. The cumulative incidence of VTE was 17% at 1 year from symptom onset and 40% by 5 years. Cardiac and pulmonary inflammatory manifestations were associated with time to VTE. M41L was positively associated specifically with pulmonary embolism by univariate (odds ratio [OR]: 4.58, confidence interval [CI] 1.28-16.21, P = .02) and multivariate (OR: 16.94, CI 1.99-144.3, P = .01) logistic regression. The cumulative incidence of arterial thrombosis was 6% at 1 year and 11% at 5 years. The overall survival of the entire patient cohort at median follow-up time of 4.8 years was 88%, and there was no difference in survival between patients with or without thrombosis (P = .8). Patients with VEXAS syndrome are at high risk of VTE; thromboprophylaxis should administered be in high-risk settings unless strongly contraindicated.
引用
- Kusne Y, Ghorbanzadeh A, Dulau-Florea A, et al. Venous and arterial thrombosis in patients with VEXAS syndrome. Blood. 2024. PMID: 38306657. doi:10.1182/blood.2023022329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。